Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 3

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Jan 21, 2023; 29(3): 487-502
Published online Jan 21, 2023. doi: 10.3748/wjg.v29.i3.487

Table 3 Drugs and vaccines used in the management and prevention of coronavirus disease 19

Classification		Drugs
Antiviral agents		Favipiravir, molnupiravir, paxlovid, remdesivir
Immunomodulatory agents
	JAK inhibitors	Baricitinib, ruxolitinib, tofacitinib
	Monoclonal antibodies to IL-6	Sarilumab, tocilizumab
	Corticosteroids	Cortisol, dexamethasone, methylprednisolone
	Monoclonal antibodies to SARS-CoV-2	Bamlanivimab, casirivimab, etesevimab, imdevimab, sotrovimab
COVID-19 vaccines
	mRNA	BNT162b2 [Pfizer-BioNTech], mRNA-1273 [Moderna]
	Adenovirus vector	ChAdOx1-S [AstraZeneca, Oxford]; Ad26.COV2.S [Johnson and Johnson, Janssen], Sputnik-V-Gam - COVID Vac Ad5+Ad26 [Gamleaya]
	Recombinant nanoparticles	NVX-CoV2373 [Novavax]
Miscellaneous agents		Azithromycin, chloroquine, dexamethasone, fluvoxamine, hydroxychloroquine, ivermectin

COVID-19: Coronavirus disease 19; IL-6: Interleukin-6; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.

Citation: Jeeyavudeen MS, Chaudhari R, Pappachan JM, Fouda S. Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease. World J Gastroenterol 2023; 29(3): 487-502
URL: https://www.wjgnet.com/1007-9327/full/v29/i3/487.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i3.487

Jeeyavudeen MS, Chaudhari R, Pappachan JM, Fouda S. Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease. World J Gastroenterol 2023; 29(3): 487-502 [PMID: 36688018 DOI: 10.3748/wjg.v29.i3.487]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.